Brokerages predict that Align Technology, Inc. (NASDAQ:ALGN) will announce $0.81 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Align Technology’s earnings. The lowest EPS estimate is $0.79 and the highest is $0.84. Align Technology reported earnings per share of $0.63 in the same quarter last year, which would indicate a positive year over year growth rate of 28.6%. The company is scheduled to announce its next earnings report on Monday, November 6th.

On average, analysts expect that Align Technology will report full year earnings of $3.40 per share for the current year, with EPS estimates ranging from $3.33 to $3.51. For the next fiscal year, analysts forecast that the business will post earnings of $4.12 per share, with EPS estimates ranging from $3.79 to $4.40. Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Align Technology.

Align Technology (NASDAQ:ALGN) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.85 EPS for the quarter, topping the consensus estimate of $0.73 by $0.12. The business had revenue of $356.50 million for the quarter, compared to analyst estimates of $343.43 million. Align Technology had a net margin of 19.18% and a return on equity of 23.87%. Align Technology’s quarterly revenue was up 32.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.62 earnings per share.

ALGN has been the subject of several recent research reports. Morgan Stanley restated an “overweight” rating and issued a $175.00 price objective on shares of Align Technology in a report on Monday, June 19th. They noted that the move was a valuation call. Credit Suisse Group reiterated an “outperform” rating and set a $170.00 target price (up from $140.00) on shares of Align Technology in a report on Thursday, July 13th. Northcoast Research reissued a “buy” rating and set a $186.00 target price (up previously from $164.00) on shares of Align Technology in a research report on Wednesday, June 21st. Zacks Investment Research downgraded shares of Align Technology from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 21st. Finally, Leerink Swann raised their target price on shares of Align Technology from $149.00 to $194.00 and gave the company an “outperform” rating in a research report on Monday, June 26th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $179.82.

Shares of Align Technology (NASDAQ:ALGN) traded down 0.19% during midday trading on Tuesday, reaching $186.86. 80,314 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $179.89 and its 200 day moving average price is $150.45. Align Technology has a 12-month low of $83.27 and a 12-month high of $190.04. The company has a market cap of $14.98 billion, a price-to-earnings ratio of 63.99 and a beta of 1.54.

Large investors have recently added to or reduced their stakes in the company. American Century Companies Inc. grew its position in shares of Align Technology by 16.5% in the 1st quarter. American Century Companies Inc. now owns 9,461 shares of the medical equipment provider’s stock worth $1,085,000 after buying an additional 1,337 shares during the last quarter. UBS Asset Management Americas Inc. lifted its position in Align Technology by 40.5% during the first quarter. UBS Asset Management Americas Inc. now owns 182,595 shares of the medical equipment provider’s stock valued at $20,945,000 after acquiring an additional 52,601 shares during the last quarter. Neuberger Berman Group LLC lifted its position in Align Technology by 11.7% during the first quarter. Neuberger Berman Group LLC now owns 4,538 shares of the medical equipment provider’s stock valued at $521,000 after acquiring an additional 474 shares during the last quarter. BB&T Securities LLC purchased a new stake in Align Technology during the first quarter valued at approximately $305,000. Finally, Credit Agricole S A lifted its position in Align Technology by 46.1% during the first quarter. Credit Agricole S A now owns 57,174 shares of the medical equipment provider’s stock valued at $6,558,000 after acquiring an additional 18,029 shares during the last quarter. Institutional investors and hedge funds own 81.57% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/03/zacks-brokerages-expect-align-technology-inc-algn-to-post-0-81-eps.html.

Align Technology Company Profile

Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.

Get a free copy of the Zacks research report on Align Technology (ALGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Align Technology (NASDAQ:ALGN)

Receive News & Stock Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related stocks with our FREE daily email newsletter.